Lyra Therapeutics reports positive ENLIGHTEN 2 Phase 3 trial: LYR-210 meets primary endpoint in CRS (p=0.0078)

Lyra Therapeutics, Inc.

ENLIGHTEN 2 met primary endpoint: LYR-210 improved 3CS composite score vs sham at 24 weeks (-1.13, p=0.0078) in non-polyp patients.
Key secondary endpoints met in full population: 3CS (p=0.0209) and SNOT-22 (-8.7, p=0.0101) at 24 weeks; SNOT-22 improvement seen from week 4.
LYR-210 well-tolerated with safety similar to sham; pooled analysis in 64 nasal polyp patients showed positive trends in multiple endpoints.
Company plans to align with FDA on NDA submission in non-polyp patients and continue development in nasal polyp patients.
Effective May 27, 2025, company effected a 1-for-50 reverse stock split (ticker unchanged LYRA).

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Lyra Therapeutics, Inc.: Certificate of Amendment to Restated Certificate of Incorporation to effect a 1-for-50 reverse stock split, effective May 27, 2025 at 5:00 p.m. Eastern Time (effective 2025-05-27).

Change: charter amendment
Effective: 2025-05-27

Exact text from the filing

On May 27, 2025, Lyra Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to its Restated Certificate of Incorporation, as amended (the “Charter Amendment”) with the Secretary of State of the State of Delaware to effect a 1-for-50 reverse stock split (the “Reverse Stock Split”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), effective May 27, 2025 at 5:00 p.m., Eastern Time (the “Effective Time”)

View on SEC.gov

42 governance changes filed in the last 30 days. Browse all governance changes →

Lyra Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-132774

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.